184 related articles for article (PubMed ID: 19528520)
41. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Zachry WM; Doan QD; Clewell JD; Smith BJ
Epilepsia; 2009 Mar; 50(3):493-500. PubMed ID: 18616554
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcomes associated with brand-to-generic phenytoin interchange.
Kinikar SA; Delate T; Menaker-Wiener CM; Bentley WH
Ann Pharmacother; 2012 May; 46(5):650-8. PubMed ID: 22550275
[TBL] [Abstract][Full Text] [Related]
43. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
Layton S; Barbeau M
Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
[TBL] [Abstract][Full Text] [Related]
44. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
Lage MJ; Gross GN; Brewster C; Spalitto A
Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
[TBL] [Abstract][Full Text] [Related]
45. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
[TBL] [Abstract][Full Text] [Related]
46. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
[TBL] [Abstract][Full Text] [Related]
47. Prescription drug costs and the generic dispensing ratio.
Liberman JN; Roebuck MC
J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
[TBL] [Abstract][Full Text] [Related]
48. [Low prescription rates of generic lamotrigine and gabapentine].
Mattsson P; Lindqvist T
Lakartidningen; 2008 Feb 6-12; 105(6):385. PubMed ID: 18380362
[No Abstract] [Full Text] [Related]
49. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting.
Dragomir A; Côté R; White M; Lalonde L; Blais L; Bérard A; Perreault S
Value Health; 2010; 13(1):87-94. PubMed ID: 19695008
[TBL] [Abstract][Full Text] [Related]
50. [Topiramate as an example of using generics in the treatment of epilepsy].
Rudakova IG; Kotov AS; Belova IuA
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(3):38-43. PubMed ID: 21423114
[TBL] [Abstract][Full Text] [Related]
51. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures.
Mark TL; Gibson TM; McGuigan K; Chu BC
Am J Psychiatry; 2010 Oct; 167(10):1202-9. PubMed ID: 20713497
[TBL] [Abstract][Full Text] [Related]
52. [The use of topamax in the treatment of epilepsy: clinical and pharmacoeconomic aspects].
Gekht AB; Mil'chakova LE; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):40-4. PubMed ID: 18427458
[TBL] [Abstract][Full Text] [Related]
53. Topiramate use and the risk of glaucoma development: a population-based follow-up study.
Ho JD; Keller JJ; Tsai CY; Liou SW; Chang CJ; Lin HC
Am J Ophthalmol; 2013 Feb; 155(2):336-341.e1. PubMed ID: 23022160
[TBL] [Abstract][Full Text] [Related]
54. Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations.
Tsadok MA; Jackevicius CA; Rahme E; Essebag V; Eisenberg MJ; Humphries KH; Tu JV; Behlouli H; Joo J; Pilote L
CMAJ; 2011 Sep; 183(12):E817-23. PubMed ID: 21746822
[TBL] [Abstract][Full Text] [Related]
55. A pilot study of topiramate dosages for migraine prophylaxis in an Asian population.
Lo YL; Lum SY; Fook-Chong S; Siow HC
J Headache Pain; 2010 Apr; 11(2):175-8. PubMed ID: 20143246
[TBL] [Abstract][Full Text] [Related]
56. Effects of a consumer driven health plan on pharmaceutical spending and utilization.
Parente ST; Feldman R; Chen S
Health Serv Res; 2008 Oct; 43(5 Pt 1):1542-56. PubMed ID: 18479407
[TBL] [Abstract][Full Text] [Related]
57. Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.
Hansen RA; Qian J; Berg RL; Linneman JG; Seoane-Vazquez E; Dutcher S; Raofi S; Page CD; Peissig PL
Clin Pharmacol Ther; 2018 Feb; 103(2):310-317. PubMed ID: 27981563
[TBL] [Abstract][Full Text] [Related]
58. Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin.
Maliepaard M; Banishki N; Gispen-de Wied CC; Teerenstra S; Elferink AJ
Eur J Clin Pharmacol; 2011 Oct; 67(10):1007-16. PubMed ID: 21494766
[TBL] [Abstract][Full Text] [Related]
59. Use of topiramate and risk of glaucoma: a case-control study.
Etminan M; Maberley D; Mikelberg FS
Am J Ophthalmol; 2012 May; 153(5):827-30. PubMed ID: 22265151
[TBL] [Abstract][Full Text] [Related]
60. Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy.
Terman SW; Lin CC; Kerr WT; DeLott LB; Callaghan BC; Burke JF
Neurology; 2022 Aug; 99(8):e751-e761. PubMed ID: 35705496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
